Fludarabine Phosphate 25 mg/mL (Fludarabine Phosphate INJECTION) 25 mg/mL

Fludarabine Phosphate 25 mg/mL is an injectable medication used for specific medical conditions. This intravenous solution is designed for targeted treatment and is supplied in single-dose vials.

Strength

25 mg/mL

Pack Size

1 VIAL, SINGLE-DOSE in 1 CARTON (0527-1242-02) / 2 mL in 1 VIAL, SINGLE-DOSE

Manufacturer / TM Owner

Lannett Company, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Fludarabine Phosphate is primarily used in the management of certain types of cancer. It works by interfering with the growth of cancer cells, making it a key component in chemotherapy regimens. Patients often wonder, 'What is Fludarabine Phosphate used for?' It is typically prescribed for conditions where cell growth needs to be controlled.

Side Effects

Common effects of Fludarabine Phosphate may include fatigue, nausea, and a temporary decrease in blood cell counts. These effects can vary from person to person and are generally managed under medical supervision. Always consult a healthcare provider for personalized advice.

Precautions & Warnings

Fludarabine Phosphate should be handled with care, as it is a potent medication. It is important to follow proper administration guidelines and storage conditions to ensure safety. Patients should be monitored regularly for any adverse reactions.

Avoid Interactions

Fludarabine Phosphate may interact with other medications, including those that affect the immune system or blood cell production. It is crucial to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and certain supplements may also impact its effectiveness.

References

Frequently Asked Questions

Fludarabine Phosphate is used in the treatment of certain types of cancer, particularly those involving rapid cell growth.

Fludarabine Phosphate is administered intravenously, typically in a clinical setting under medical supervision.

Common side effects may include fatigue, nausea, and a temporary decrease in blood cell counts.

Fludarabine Phosphate may interact with other medications, so it is important to consult a healthcare provider before combining treatments.

Fludarabine Phosphate should be stored according to the manufacturer's guidelines to maintain its efficacy and safety.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.